Result:Good· Market: Surged#Margin expansion#Broad based
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 46.97 | 2.6% | 18.7% |
| Total Income | 47.53 | 3.4% | 18.9% |
| Expenditure | 44.30 | 1.4% | 17.5% |
| PBT | 3.23 | 40.0% | 41.3% |
| Net Profit | 2.37 | 26.0% | 57.9% |
| OPM | 12.93% | 1.95pp | 1.64pp |
| NPM | 4.98% | 0.90pp | 1.23pp |
| EPS | 1.88 | 26.2% | 58.0% |
Revenue grew 18.7% YoY with PAT up 57.8% on genuine margin expansion (OPM 11.3%→12.9%, NPM 3.8%→5.0%), solid core-business-driven growth for a small pharma manufacturer, though the profit base remains modest.
Informational and educational content only. Not investment advice.